News

Veterans Exploring Treatment Solutions (VETS) Applauds White House Executive Order Advancing Ibogaine Research, Urges Accelerated Scientific Investment

MDMA and the FDA, Take Two

VETS Policy Director Logan Davidson weighs in on Resilient Pharmaceuticals' renewed FDA application for MDMA-assisted therapy, calling it a meaningful step toward the rigorous, science-backed treatment options veterans with treatment-resistant PTSD deserve.

Legislative Progress Q2 2026: Building the Infrastructure for What Comes Next

A look at Q2 2026's legislative progress on veteran access to psychedelic-assisted therapy, from new state research funding and trigger laws to a federal Executive Order and VETS-led advocacy days at statehouses in North Carolina and Massachusetts.

Understanding the Healing Journey: Dr. Lori Camper on Preparation, Integration, and What Comes After Psychedelic-Assisted Therapy

In this conversation, VETS Programs Director Dr. Lori Camper shares what preparation, integration, and support truly look like for veterans exploring psychedelic-assisted therapy, and why the work that happens before and after treatment matters just as much as the experience itself.

VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans

President Trump announced that HHS Secretary RFK Jr. received the University of Miami's original 1994 ibogaine FDA application to accelerate psychedelic research access for veterans, with VETS co-founder and CEO Amber Capone comments that "veterans need to understand that these treatments are not for everyone and they need careful screening, medical oversight, preparation, and follow-up."

VETS Applauds Massachusetts House Passage of Psychedelic-Assisted Therapy Pilot Program

Veteran Advocates Thank House Leadership for Advancing Landmark Legislation and Urge the Senate to Retain the Provision in Economic Development Bill

The Second Homecoming: What Freedom Means After Service

This blog explores how true freedom after military service is found in healing, reconnection, and the ongoing journey home for veterans and their families.

Massachusetts House Advances Psychedelic Therapy Pilot Program

Massachusetts lawmakers advanced legislation to create a five-year psychedelic-assisted therapy pilot program, with VETS playing a key advocacy role by supporting the measure and celebrating it as a major step toward expanding safe, regulated access to psychedelic-assisted therapy for veterans and others with serious mental health conditions.

Utahns are traveling abroad for ibogaine, while experts voice both optimism and caution around the emerging drug.

The article spotlights VETS Foundational Healing Grant recipient Kyle Bingham, a former Green Beret who shares how ibogaine treatment and ongoing integration support helped him better manage PTSD while underscoring the promise and complexities of psychedelic-assisted therapy.

Why Are Republicans Suddenly for Ibogaine?

The article highlights VETS’ leadership in expanding access to psychedelic-assisted therapy, showcasing how the organization funds veterans’ ibogaine treatment abroad, provides critical integration support, and advances state and federal policy efforts to accelerate research and establish safe, regulated clinical access in the United States.